3,4-Dehydro-chlorbenzol | 14091-35-1

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 乙烯基卤化物
• 英文名称: 3,4-Dehydro-chlorbenzol
• 英文别名: 4-Chlorbenzin；4-Chlor-1.2-dehydrobenzol；4-Chlor-dehydrobenzol；4-Chlorbenzyn；2-Chlorocyclohexa-1,3-dien-5-yne；2-chlorocyclohexa-1,3-dien-5-yne
• CAS: 14091-35-1
• 化学式: C₆H₃Cl
• 分子量: 110.543
• InChiKey: BVEAAQHCFUTRPY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

文献信息

• [EN] ANTIMICROBIAL AGENTS<br/>[FR] AGENTS ANTIMICROBIENS
  申请人：UNIV RUTGERS

  公开号：WO2014074932A1

  公开（公告）日：2014-05-15

  The invention provides compounds of formula (I): wherein R1-R3, n, and W have any of the values defined in the specification, and salts thereof. The compounds have good solubility and are useful for treating bacterial infections.

  该发明提供了式（I）的化合物：其中R1-R3，n和W具有规范中定义的任何值，以及其盐。这些化合物具有良好的溶解性，并可用于治疗细菌感染。
• Piperidinyl derivatives as modulators of chemokine receptor activity
  申请人：Bristol-Myers Squibb Company

  公开号：EP2471773B1

  公开（公告）日：2016-03-23
• BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS INHIBITORS
  申请人：Janssen Sciences Ireland UC

  公开号：EP2651903B1

  公开（公告）日：2016-03-23
• [EN] BICYCLIC AND TRICYCLIC INHIBITORS OF SUMOYLATION ENZYMES AND METHODS FOR THEIR USE<br/>[FR] INHIBITEURS BICYLIQUES ET TRICYCLIQUES D'ENZYMES DE SUMOYLATION ET LEURS PROCÉDÉS D'UTILISATION
  申请人：CHEN YUAN

  公开号：WO2012064897A2

  公开（公告）日：2012-05-18

  According to the embodiments described herein, a tricyclic SUMOylation inhibitor compound is provided. In some embodiments, a method for inhibiting a SUMOylation enzyme in a cell is provided. Such a method may include administering a SUMOylation inhibitor compound to the cell. In some aspects, the SUMOylation enzyme is SUMO E1 or SUMO E2. In some aspects, the method may be used to inhibit a cancer cell in vitro (e.g., grown in culture) or in vivo (e.g., as part of a tumor in a subject). In other embodiments, a method for treating a cancer is provided. Such a method may include administering an effective amount of a pharmaceutical composition to a subject having the cancer. The pharmaceutical composition may include a SUMOylation inhibitor compound. In some embodiments, the method for treating a disease may further comprise administering one or more DNA-damaging therapy in combination with administration of the pharmaceutical composition.
• [EN] FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF<br/>[FR] COMPOSÉS À CYCLES FUSIONNÉS, COMPOSITION PHARMACEUTIQUE ET UTILISATIONS ASSOCIÉES
  申请人：SHANGHAI DE NOVO PHARMATECH CO LTD

  公开号：WO2016131381A1

  公开（公告）日：2016-08-25

  This disclosure is related to a fused-ring compound of formula (I) and/or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the fused ring compound of formula (I) and/or a pharmaceutically acceptable salt thereof, preparation methods thereof, and use thereof in modulating activity of indoleamine 2, 3-dioxygenase (IDO) and/or tryptophan 2, 3-dioxygenase (TDO); this disclosure further provides methods of treating IDO and/or TDO-associated diseases, including cancer, viral infection and autoimmune diseases.